DE69512589D1 - Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase - Google Patents

Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase

Info

Publication number
DE69512589D1
DE69512589D1 DE69512589T DE69512589T DE69512589D1 DE 69512589 D1 DE69512589 D1 DE 69512589D1 DE 69512589 T DE69512589 T DE 69512589T DE 69512589 T DE69512589 T DE 69512589T DE 69512589 D1 DE69512589 D1 DE 69512589D1
Authority
DE
Germany
Prior art keywords
diseases caused
acyl coa
coa cholesterol
sebaceous gland
sebum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69512589T
Other languages
English (en)
Other versions
DE69512589T2 (de
Inventor
James T Mayne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Graceway Pharmaceuticals LLC
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69512589D1 publication Critical patent/DE69512589D1/de
Application granted granted Critical
Publication of DE69512589T2 publication Critical patent/DE69512589T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69512589T 1994-08-31 1995-08-10 Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase Expired - Lifetime DE69512589T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/298,735 US6133326A (en) 1994-08-31 1994-08-31 Compositions and methods for decreasing sebum production

Publications (2)

Publication Number Publication Date
DE69512589D1 true DE69512589D1 (de) 1999-11-11
DE69512589T2 DE69512589T2 (de) 2000-01-27

Family

ID=23151816

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69512589T Expired - Lifetime DE69512589T2 (de) 1994-08-31 1995-08-10 Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase

Country Status (9)

Country Link
US (2) US6133326A (de)
EP (1) EP0699439B1 (de)
JP (2) JP3266473B2 (de)
AT (1) ATE185271T1 (de)
CA (1) CA2157142C (de)
DE (1) DE69512589T2 (de)
DK (1) DK0699439T3 (de)
ES (1) ES2136252T3 (de)
GR (1) GR3031917T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU769224B2 (en) * 1998-12-28 2004-01-22 Taisho Pharmaceutical Co., Ltd. External preparation
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
EA004255B1 (ru) 2000-02-02 2004-02-26 Уорнер-Ламберт Компани Применение 2,6-диизопропилфенилового эфира [(2,4,6-триизопропилфенил)ацетил]сульфаминовой кислоты в качестве ингибитора секреции сальных желез, в частности, для лечения акне и композиции и способы на основе данного соединения
AU2002350088A1 (en) * 2001-06-22 2003-01-08 Millard Marsden Mershon Compositions and methods for reducing blood and fluid loss from open wounds
EP1281399A3 (de) * 2001-08-01 2004-02-11 Warner-Lambert Company Hemmer mit doppelter Wirkung auf Wachsester- und Cholesterylestersynthese zur Hemmung der Sebumproduktion
WO2003075908A1 (en) * 2002-03-12 2003-09-18 Galderma Research & Development, S.N.C. Use of adapalene for the treatment of dermatological disorders
JP2005060386A (ja) * 2003-07-29 2005-03-10 Rohto Pharmaceut Co Ltd 皮膚外用剤
JP2009102358A (ja) * 2003-07-29 2009-05-14 Rohto Pharmaceut Co Ltd 皮膚外用剤
RU2342930C2 (ru) * 2003-10-09 2009-01-10 Уорнер-Ламберт Компани Ллс Фармацевтические композиции, содержащие малонамидные производные для уменьшения продукции кожного сала
KR100906288B1 (ko) * 2005-02-24 2009-07-06 워너-램버트 캄파니 엘엘씨 결정질 ａｃａｔ 억제제
FR2918889B1 (fr) * 2007-07-19 2009-10-23 Galderma Res & Dev Utilisation de l'eflucimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal
FR2918890A1 (fr) * 2007-07-19 2009-01-23 Galderma Res & Dev Utilisation du pactimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal
FR2920771B1 (fr) * 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de phenylurees, inhibiteurs de l'enzymes soat-1, compositions pharmaceutiques et cosmetiques les contenant
FR2920769B1 (fr) 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
CN101502541B (zh) * 2008-02-04 2011-12-28 成都地奥九泓制药厂 安息香属植物及其提取物的用途
FR2946342B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946340B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946345B1 (fr) 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946346B1 (fr) 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
EP3463277A4 (de) 2016-06-06 2020-01-01 GDD Therapeutics, LLC Formulierungen für substituierte 3-pyrrolidine, zusammensetzungen damit und verwendungen davon

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4302456A (en) * 1977-04-13 1981-11-24 The Upjohn Company Process for therapeutic treatment
US4514385A (en) * 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
DE3580134D1 (de) 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem Benzoesaeurederivate.
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4751026A (en) 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja) 1986-07-11 1988-02-01 ワ−ナ−−ランバ−ト・コンパニ− Ω−（置換フエニルオキシ）−アルカン酸のアリ−ル−およびアラルキルアミド
US4743605A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
US4716175A (en) * 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
IE61716B1 (en) 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
ES2037768T3 (es) 1987-07-02 1993-07-01 Warner-Lambert Company Procedimiento para preparar n-(fenil(2,6-disustituido))-ureas y carbamatos inhibidores de acil-coa: colesterol acil-transferasa.
US5116848A (en) 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5155127A (en) 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) * 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
CA2022346A1 (en) 1989-08-04 1991-02-05 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
TW205037B (de) 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
DK0623112T3 (da) * 1992-01-23 1999-08-30 Pfizer 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi
SK142694A3 (en) * 1992-05-28 1995-06-07 Pfizer N-aryl and n-heteroarylurea derivatives as inhibitors of acylcoenzyme a:cholesterol-acyltransferase, pharmaceutical preparations contains these compounds and use
US5902805A (en) * 1996-04-22 1999-05-11 L'oreal Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
US5834480A (en) * 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
US5994330A (en) * 1998-11-09 1999-11-30 El Khoury; Georges F. Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
US9206485B2 (en) 2011-08-19 2015-12-08 J. Edwin Roy Portable sugar mill
US9303539B1 (en) 2012-06-10 2016-04-05 Ags I-Prop, Llc Universal drain plug system and method
US9210886B2 (en) 2014-03-27 2015-12-15 Monsanto Technology Llc Plants and seeds of corn variety CV410274

Also Published As

Publication number Publication date
JP3266473B2 (ja) 2002-03-18
CA2157142C (en) 1998-06-09
US6133326A (en) 2000-10-17
JP2002053494A (ja) 2002-02-19
US6271268B1 (en) 2001-08-07
CA2157142A1 (en) 1996-03-01
GR3031917T3 (en) 2000-03-31
EP0699439B1 (de) 1999-10-06
ATE185271T1 (de) 1999-10-15
ES2136252T3 (es) 1999-11-16
EP0699439A3 (de) 1996-06-26
JPH0899903A (ja) 1996-04-16
EP0699439A2 (de) 1996-03-06
DK0699439T3 (da) 1999-12-27
DE69512589T2 (de) 2000-01-27

Similar Documents

Publication Publication Date Title
DE69512589D1 (de) Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
ATE332687T1 (de) Liponsäure in topischen mittel
DE69939651D1 (de) Behandlung hyperproliferativer erkrankungen
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE69617469D1 (de) Behandlung von multipler sklerose
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
BR9708460A (pt) Composto, composição farmacêutica e processo para prevenir ou tratar uma condição patológica em um humano ou animal não-humano.
BR0313630A (pt) Composição para aplicação tópica, sistema para o tratamento de caspa, métodos para o tratamento e/ou prevenção da caspa e da coceira do couro cabeludo e usos de uma combinação sinérgica
BR9510488A (pt) Formulações e métodos para redução da irritação da pele
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
BR9712792A (pt) Inibidores de metaloprotease bidentada.
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA200100791A1 (ru) Ингибиторы аминотрансфераз, зависимых от аминокислот с разветвленной цепью, и их применение в лечении диабетической ретинопатии
BRPI0415136A (pt) método para a diminuição da produção de sebo
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
BR0107954A (pt) Inibidores duplos de sìntese de éster de colesterol e éster de cera para distúrbios de glândula sebácea

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GRACEWAY PHARMACEUTICALS, LLC, BRISTOL, TENN., US

R082 Change of representative

Ref document number: 699439

Country of ref document: EP

Representative=s name: LEDERER & KELLER, 80538 MUENCHEN, DE